NORTECH SYSTEMS INC 10-Q

nsys20220331_10q.htm       UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549   FORM   10-Q   (Mark One)     ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934   For the quarterly period ended March 31, 2022   OR     ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934   For the transition period from            to              NORTECH SYSTEMS INCORPORATED   Commission file number 0-13257   State of Incorporation: Minnesota   IRS Employer Identification No.  41-1681094   Executive Offices: 7550 Meridian Circle N., Suite   # 150 , Maple Grove , MN 55369   Telephone number: ( 952 ) 345-2244   Securities registered pursuant to Section 12(b) of the Act:   Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $.01 per share NSYS   NASDAQ Capital Market    Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  Yes ☒ No ☐   Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulations S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).  Yes ☒ No ☐   Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company.  See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.     Large Accelerated Filer ☐ Accelerated Filer ☐   Non-accelerated Filer ☒ Smaller Reporting Company ☒   Emerging growth company ☐     If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐       Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).  Yes ☐ No ☒   Number of shares of $.01 par value common stock outstanding at May 5, 2022 was 2,682,064 .   1       TABLE OF CONTENTS   PAGE PART I - FINANCIAL INFORMATION               Item 1 - Financial Statements                   Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) 3                 Condensed Consolidated Balance Sheets 4                 Condensed Consolidated Statements of Cash Flows 5                 Condensed Consolidated Statements of Shareholders’ Equity 6                 Condensed Notes to Consolidated Financial Statements 7             Item 2 - Management's Discussion and Analysis of Financial Condition And Results of Operations 18             Item 3 - Quantitative and Qualitative Disclosures About Market Risk 25             Item 4 - Controls and Procedures 27                     PART II - OTHER INFORMATION               Item 1 - Legal Proceedings 26             Item 1A. - Risk Factors 26             Item 2 - Unregistered Sales of Equity Securities, Use of Proceeds 26             Item 3 - Defaults on Senior Securities 26             Item 4 - Mine Safety Disclosures 26             Item 5 - Other Information 26             Item 6 - Exhibits 27           SIGNATURES 28   2       PART   ITEM 1. FINANCIAL STATEMENTS   NORTECH SYSTEMS INCORPORATED AND SUBSIDIARIES   CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) (UNAUDITED) (IN THOUSANDS, EXCEPT SHARE DATA)       THREE MONTHS ENDED MARCH 31,       2022     2021                     Net Sales   $ 30,711     $ 22,072                     Cost of Goods Sold     26,667       20,511                     Gross Profit     4,044       1,561                     Operating Expenses                 Selling Expenses     833       721   General and Administrative Expenses     2,729       2,796   Research and Development Expenses     328       -   Restructuring Charges     -       219   Gain on Sale of Assets     ( 15 )     -                     Total Operating Expenses     3,875       3,736                     Income (Loss) From Operations     169       ( 2,175 )                   Other Expense                 Interest Expense     ( 98 )     ( 86 )                   Income (Loss) Before Income Taxes     71       ( 2,261 )                   Income Tax Benefit     ( 67 )     ( 707 )                   Net Income (Loss)   $ 138     $ ( 1,554 )                   Net Income (Loss) Per Common Share:                                   Basic (in dollars per share)   $ 0.05     $ ( 0.58 ) Weighted Average Number of Common Shares Outstanding - Basic (in shares)     2,680,731       2,659,132                     Diluted (in dollars per share)   $ 0.05     $ ( 0.58 ) Weighted Average Number of Common Shares Outstanding - Diluted (in shares)     2,871,901       2,659,132                     Other comprehensive income (loss)                 Foreign currency translation     5       ( 34 ) Comprehensive income (loss), net of tax   $ 143     $ ( 1,588 )   See Accompanying Condensed Notes to Condensed Consolidated Financial Statements   3       NORTECH SYSTEMS INCORPORATED AND SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS  (IN THOUSANDS, EXCEPT SHARE DATA)         MARCH 31, 2022       DECEMBER 31, 2021 (1)   ASSETS   (Unaudited)           Current Assets                 Cash   $ 841     $ 643   Restricted Cash     776       1,582   Accounts Receivable, less allowances of $ 366 and $ 328     14,695       14,548   Employee Retention Credit Receivable     5,209       5,209   Inventories, Net     21,187       19,434   Contract Assets     8,114       8,698   Prepaid Expenses and Other Current Assets     1,996       1,660   Total Current Assets     52,818       51,774                     Property and Equipment, Net     5,922       5,833   Operating Lease Assets     8,706       8,983   Other Intangible Assets, Net     465       501   Total Assets   $ 67,911     $ 67,091                     LIABILITIES AND SHAREHOLDERS' EQUITY                 Current Liabilities                 Current Portion of Finance Lease Obligations   $ 508     $ 601   Current Portion of Operating Lease Obligations     1,080       1,043   Accounts Payable     14,012       12,710   Accrued Payroll and Commissions     4,890       4,045   Other Accrued Liabilities     4,223       3,907   Total Current Liabilities     24,713       22,306                     Long-Term Liabilities                 Long Term Line of Credit     7,526       8,959   Long Term Finance Lease Obligations, Net     824       916   Long-Term Operating Lease Obligations, Net     8,411       8,695   Other Long-Term Liabilities     102       104   Total Long-Term Liabilities     16,863       18,674                     Total Liabilities     41,576       40,980                     Commitments and Contingencies                                       Shareholders' Equity                 Preferred Stock, $ 1 par value; 1,000,000 Shares Authorized: 250,000 Shares Issued and Outstanding     250       250   Common Stock - $ 0.01 par value; 9,000,000 Shares Authorized: 2,682,064 and 2,672,064 Shares Issued and Outstanding, respectively     27       27   Additional Paid-In Capital     16,043       15,962   Accumulated Other Comprehensive Loss     61       56   Retained Earnings     9,954       9,816   Total Shareholders' Equity     26,335       26,111   Total Liabilities and Shareholders' Equity   $ 67,911     $ 67,091     See Accompanying Condensed Notes to Condensed Consolidated Financial Statements (1) The balance sheet at December 31, 2021 has been derived from the audited financial statements at that date   4       NORTECH SYSTEMS INCORPORATED AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) (IN THOUSANDS)         THREE MONTHS ENDED MARCH 31,       2022     2021   CASH FLOWS FROM OPERATING ACTIVITIES                 Net Income (Loss)   $ 138     $ ( 1,554 ) Adjustments to Reconcile Net Income (Loss) to Net Cash                 Provided By (Used In) Operating Activities:                 Depreciation and Amortization     486       477   Compensation on Stock-Based Awards     48       21   Compensation on Equity Appreciation Rights     -       13   Loss on Held for Sales     -       28   (Gain) Loss on Disposal of Property and Equipment     ( 15 )     31   Change in Accounts Receivable Allowance     38       379   Change in Inventory Reserves     97       ( 394 ) Changes in Current Operating Items                 Accounts Receivable     ( 188 )     2,732   Inventories     ( 1,852 )     ( 2,777 ) Contract Assets     585       ( 778 ) Prepaid Expenses and other Curent Assets     ( 263 )     ( 299 ) Income Taxes     ( 168 )     ( 796 ) Accounts Payable     1,302       1,553   Accrued Payroll and Commissions     845       721   Other Accrued Liabilities     438       ( 253 ) Net Cash Provided By (Used In) Operating Activities     1,491       ( 896 )                   CASH FLOWS FROM INVESTING ACTIVITIES                 Proceeds from Sale of Property and Equipment     15       -   Purchase of Intangible Asset     -       ( 64 ) Purchases of Property and Equipment     ( 529 )     ( 208 ) Net Cash Used In Investing Activities     ( 514 )     ( 272 )                   CASH FLOWS FROM FINANCING ACTIVITIES                 Net Change in Line of Credit     ( 1,434 )     ( 1,128 ) Principal Payments on Long-Term Debt     -       ( 125 ) Principal Payments on Financing Leases     ( 184 )     ( 162 ) Stock Option Excercises     33       -   Net Cash Provided Used In Financing Activities     ( 1,585 )     ( 1,415 )                   Effect of Exchange Rate Changes on Cash     -       1                     Net Change in Cash and Cash Equivalents     ( 608 )     ( 2,582 ) Cash and Cash Equivalents - Beginning of Year     2,225       3,564   Cash and Cash Equivalents - End of Year   $ 1,617     $ 982                     Reconciliation of cash and restricted cash reported within the consolidated balance sheets                 Cash   $ 841     $ 384   Restricted Cash     776       598   Total Cash and restricted cash reported in the consolidated statements of cash flows   $ 1,617     $ 982   Supplemental Disclosure of Cash Flow Information:                 Cash Paid During the Period for Interest   $ 94     $ 59   Cash Paid During the Period for Income Taxes     -       97                     Supplemental Noncash Investing and Financing Activities:                 Property and Equipment Purchases in Accounts Payable     -       214   Property Acquired Under Operating Lease     -       858     See Accompanying Condensed Notes to Condensed Consolidated Financial Statements   5       NORTECH SYSTEMS INCORPORATED AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY (UNAUDITED) (IN THOUSANDS)       Preferred Stock     Common Stock     Additional Paid-In Capital     Accumulated Other Comprehensive Loss     Retained Earnings     Total Shareholders' Equity                                                     BALANCE DECEMBER 31, 2020   $ 250     $ 27     $ 15,816     $ ( 37 )   $ 2,662     $ 18,718   Net Loss     -       -       -       -       ( 1,554 )     ( 1,554 ) Foreign currency translation adjustment     -       -       -       ( 34 )     -       ( 34 ) Compensation on stock-based awards     -       -       21       -       -       21                                                     BALANCE MARCH 31, 2021   $ 250     $ 27     $ 15,837     $ ( 71 )   $ 1,108     $ 17,151                                                     BALANCE DECEMBER 31, 2021   $ 250     $ 27     $ 15,962     $ 56     $ 9,816     $ 26,111   Net Income     -       -       -       -       138       138   Foreign currency translation adjustment     -       -       -       5       -       5   Stock option exercises     -       -       33       -       -       33   Compensation on stock-based awards     -       -       48       -       -       48                                                     BALANCE MARCH 31, 2022   $ 250     $ 27     $ 16,043     $ 61     $ 9,954     $ 26,335     See Accompanying Condensed Notes to Condensed Consolidated Financial Statements   6     CONDENSED NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (DOLLARS IN THOUSANDS, EXCEPT SHARE AND PER SHARE DATA) (UNAUDITED)     NOTE 1. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES   Basis of Presentation The accompanying unaudited condensed consolidated financial statements for the interim periods have been prepared in accordance with Generally Accepted Accounting Principles in the United States of America (“GAAP”) for interim financial information and pursuant to the rules and regulations of the Securities and Exchange Commission. Accordingly, they do not include all of the financial information and footnotes required by GAAP for complete financial statements, although we believe the disclosures are adequate to make the information presented not misleading. It is suggested that these condensed consolidated financial statements be read in conjunction with the consolidated financial statements and the notes thereto included in our Annual Report on Form 10 -K for the year ended December 31, 2021. The operating results for the interim periods presented are not necessarily indicative of the results expected for the full year or for any other interim period. In our opinion, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been included.   The preparation of financial statements in conformity with GAAP requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. In preparing these condensed consolidated financial statements, we have made our best estimates and judgments of certain amounts included in the condensed consolidated financial statements, giving due consideration to materiality. Changes in the estimates and assumptions used by us could have a significant impact on our financial results, since actual results could differ from those estimates.   Principles of Consolidation The condensed consolidated financial statements include the accounts of Nortech Systems Incorporated and its wholly owned subsidiaries. All significant intercompany accounts and transactions have been eliminated.   Revenue Recognition Our revenue is comprised of product, engineering services and repair services. All revenue is recognized when the Company satisfies its performance obligation(s) under the contract by transferring the promised product or service to our customer either when (or as) our customer obtains control of the product or service, with the majority of our revenue being recognized over time including goods produced under contract manufacturing agreements and services revenue. A performance obligation is a promise in a contract to transfer a distinct product or service to a customer. A contract’s transaction price is allocated to each distinct performance obligation. The majority of our contracts have a single performance obligation. Revenue is recorded net of returns, allowances and customer discounts. Our net sales for services were less than 10% of our total sales for all periods presented, and accordingly, are included in net sales in the Condensed Consolidated Statements of Operations and Comprehensive Income (Loss). Sales, value add, and other taxes collected from customers and remitted to governmental authorities are accounted for on a net (excluded from revenues) basis. Shipping and handling costs charged to our customers are included in net sales, while the corresponding shipping expenses are included in cost of goods sold.   7     Stock-Based Awards   Stock Options In May 2017, the shareholders approved the 2017 Stock Incentive Plan which authorized the issuance of 350,000 shares. There were additional shares authorized by the shareholders in March 2020 totaling 50,000 . Since the last shareholders’ meeting, the Board of Directors has approved and is seeking shareholder approval of an additional 75,000 shares to be authorized under the plan.   We granted 21,000 service-based options and 21,000 market condition options to Jay Miller per his employment agreement signed February 27, 2022. The market condition options vest if certain stock prices are exceeded between February 27, 2024 and February 27, 2028. There were an additional 32,000 employee grants during the three months ended March 31, 2022, for a total of 74,000 options granted during the three months ended March 31, 2022. There were no options granted during the three months ended March 31, 2021.   Total compensation expense related to stock options was $ 43 and $ 21 for the three months ended March 31, 2022 and 2021, respectively. As of March 31, 2022, there was $ 816 of unrecognized compensation which will vest over the next 3.96 years.   Following is the status of all stock options as of March 31, 2022:       Shares     Weighted- Average Exercise Price Per Share     Weighted- Average Remaining Contractual Term (in years)     Aggregate Intrinsic Value (in thousands)   Outstanding - January 1, 2022     387,500     $ 4.57                   Granted     74,000       10.73                   Exercised     ( 10,000 )     3.43                   Cancelled     ( 600 )     3.29                   Outstanding - March 31, 2022     450,900     $ 5.58       7.12     $ 2,063   Exercisable - March 31, 2022     204,500     $ 3.92       6.32     $ 889     Restricted Stock Units During the three months ended March 31, 2022, we granted 21,000 restricted stock units (“RSUs”) under our 2017 Stock Incentive Plan to non-employee directors which vest over two years. There were no RSUs outstanding prior to the three months ended March 31, 2022. Total compensation expense related to the RSUs were $ 5 and $ 0 for the three months ended March 31, 2022 and 2021, respectively. Total unrecognized compensation expense related to the RSUs was $ 243 , which will vest over the next 1.96 years. The RSUs granted in the three months ended March 31, 2022 had a grant price of $ 11.80 per share with a weighted average remaining contractual term of 9.96 years. No RSUs vested during the three months ended March 31, 2022.   8     Equity Appreciation Rights Plan In November 2010, the Board of Directors adopted the Nortech Systems Incorporated Equity Appreciation Rights Plan ( “2010 Plan”). The total number of Equity Appreciation Right Units (“Units”) that can be issued under the 2010 Plan shall not exceed an aggregate of 1,000,000 Units as amended and restated on March 11, 2015. There were no units granted during the three months ended March 31, 2022 or March 31, 2021.   The 100,000 units outstanding at December 31, 2021 were paid on March 29, 2022. As of March 31, 2022, there are no units outstanding. Total compensation expense related to the vested outstanding Units based on the estimated appreciation over their remaining terms was $ 0 and $ 143 for the three months ended March 31, 2022 and 2021, respectively.   Net Income (Loss) per Common Share Basic net income (loss) per common share is computed by dividing net income (loss) by the weighted-average number of common shares outstanding. Dilutive net income (loss) per common share assumes the exercise and issuance of all potential common stock equivalents in computing the weighted-average number of common shares outstanding, unless their effect is antidilutive. All stock options and restricted stock units, while outstanding, are considered common stock equivalents. For the three months ended March 31, 2022 there were 191,170 diluted shares with $ 0.02 earnings per diluted share. For the three months ended March 31, 2021, all stock options were deemed to be antidilutive as there was a net loss and, therefore, were not included in the computation of income per common share amount.   We had outstanding stock options totaling 51,911 and RSUs totaling 21,000 that are not considered in the computation of diluted net income (loss) per share as their effect would have been anti-dilutive for the three months ended March 31, 2022.   Restricted Cash Cash and cash equivalents classified as restricted cash on our consolidated balance sheets are restricted as to withdrawal or use under the terms of certain contractual agreements. As of March 31, 2022 we had outstanding letters of credit for $ 400 in total to Essjay Bemidji Holdings, LLC and Essjay Mankato Holdings, LLC. Restricted cash as of March 31, 2022 was $ 776 . The March 31, 2022 restricted cash balance included lockbox deposits that are temporarily restricted due to timing at the period end. The lockbox deposits are applied against our line of credit the next business day.   Accounts Receivable and Allowance for Doubtful Accounts Credit is extended based upon an evaluation of the customer’s financial condition and, while collateral is not required, the Company periodically receives surety bonds that guarantee payment. Credit terms are consistent with industry standards and practices. Trade accounts receivable have been reduced by an allowance for doubtful accounts of $ 366 at March 31, 2022 and $ 328 at December 31, 2021.   9     Inventories Inventories are stated at the lower of average cost (which approximates first -in, first out) or net realizable value. Costs include material, labor, and overhead required in the warehousing and production of our products. Inventory reserves are maintained for the estimated value of the inventories that may have a lower value than stated or quantities in excess of future production needs.   Inventories are as follows:       March 31, 2022     December 31, 2021   Raw Materials   $ 20,221     $ 18,492   Work in Process     1,796       1,678   Finished Goods     565       562   Reserves     ( 1,395 )     ( 1,298 )                   Total   $ 21,187     $ 19,434     Other Intangible Assets Other intangible assets at March 31, 2022 and December 31, 2021 are as follows:       Customer Relationships     Trade Names     Patents     Total   Balance at January 1, 2021   $ 507     $ 589     $ 77     $ 1,173   Additions     -       -       64       64   Amortization     147       29       -       176   Abandonment Loss     -       560       -       560   Balance at December 31, 2021     360       -       141       501   Amortization     36       -       -       36   Balance at March 31, 2022   $ 324     $ -     $ 141     $ 465     Intangible assets are amortized on a straight-line basis over their estimated useful lives. The weighted-average remaining amortization period of our intangible assets is 2.5 years. Patents are not being amortized as they are in process and a patent has not yet been received.   Amortization expense of finite life intangible assets for the three months ended March 31, 2022 and 2021 was $ 36 and $ 46 , respectively.   Estimated future annual amortization expense ( not including the patents in process) related to these assets is approximately as follows:   Year   Amount   Remainder of 2022   $ 109   2023     145   2024     70   Total   $ 324     10     Accounting Pronouncements Issued But Not Yet Adopted In June 2016, the FASB issued ASU 2016 - 13, Measurement of Credit Losses on Financial Instruments. This guidance introduces a new model for recognizing credit losses on financial instruments based on an estimate of current expected credit losses. The ASU also provides updated guidance regarding the impairment of available-for-sale debt securities and includes additional disclosure requirements. The new guidance is effective for public business entities that meet the definition of a Smaller Reporting Company as defined by the SEC for interim and annual periods beginning after December 15, 2022. Early adoption is permitted. We are currently evaluating the impact of this standard on our consolidated financial statements and related disclosures.   In March 2020, the FASB issued ASU 2020 - 04,  Reference Rate Reform. ASU 2020 - 04 provides optional guidance for a limited period of time to ease potential accounting impact associated with transitioning away from reference rates that are expected to be discontinued, such as LIBOR. The amendments in this ASU apply only to contracts, hedging relationships, and other transactions that reference LIBOR or another reference rate expected to be discontinued. The amendments in ASU 2020 - 04 can be adopted as of March 12, 2020 and are effective through December 31, 2022. Our line of credit agreement with Bank of America was amended on December 31, 2021 to reference the Bloomberg Short-Term Bank Yield Index (BSBY) rather than LIBOR. We do not anticipate a material impact on our consolidated financial statements related to the change in index. We do not have additional material agreements that will be impacted by a change in reference rate.     NOTE 2. CONCENTRATION OF CREDIT RISK AND MAJOR CUSTOMERS   Financial instruments that potentially subject us to concentrations of credit risk consist principally of cash and accounts receivable. With regard to cash, we maintain our excess cash balances in checking accounts at primarily two financial institutions, one in the United States and one in China. The account in the United States may at times exceed federally insured limits. Of the $ 1,617 in cash and restricted cash at March 31, 2022, approximately $ 769 and $ 63 was held at banks located in China and Mexico, respectively. We grant credit to customers in the normal course of business and do not require collateral on our accounts receivable.   We have certain customers whose revenue individually represented 10% or more of net sales, or whose accounts receivable balances individually represented 10% or more of total accounts receivable. One customer accounted for 23 % and 29 % of net sales for the three months ended March 31, 2022 and 2021, respectively.   At March 31, 2022, two customers represented approximately 35 % of our total accounts receivable. At December 31, 2021, one customer represented approximately 19 % of our total accounts receivable.   Export sales represented approximately 5 % and 4 % of net sales for the three months ended March 31, 2022 and 2021, respectively.   11       NOTE 3. REVENUE   Revenue recognition Our revenue is comprised of product, engineering services and repair services. All revenue is recognized when the Company satisfies its performance obligation(s) under the contract by transferring the promised product or service to our customer either when (or as) our customer obtains control of the product or service, with the majority of our revenue being recognized over time including goods produced under contract manufacturing agreements and services revenue. A performance obligation is a promise in a contract to transfer a distinct product or service to a customer. A contract’s transaction price is allocated to each distinct performance obligation. The majority of our contracts have a single performance obligation, as the promise to transfer products or services is not separately identifiable from other promises in the contract and, therefore, not distinct.   Revenue is measured as the amount of consideration we expect to receive in exchange for transferring products or providing services. As such, revenue is recorded net of returns, allowances and customer discounts. Sales, value add, and other taxes collected from customers and remitted to governmental authorities are accounted for on a net (excluded from revenues) basis. Shipping and handling costs are included in cost of goods sold.   The majority of our revenue is derived from the transfer of goods produced under contract manufacturing agreements which have no alternative use and we have an enforceable right to payment for our performance completed to date. Our performance obligations within our contract manufacturing agreements are generally satisfied over time as the goods are produced based on customer specifications and we have an enforceable right to payment for the goods produced. Revenue under contract manufacturing agreements that was recognized over time accounted for approximately 73 % and 75 % of our revenue for the three months ended March 31, 2022 and 2021, respectively. Revenues under these agreements are generally recognized over time using an input measure based upon the proportion of actual costs incurred. If these requirements are not met, the revenue is recognized at a point in time, generally upon shipment.   Accounting for contract manufacturing agreements involves the use of various techniques to estimate total revenue and costs. We estimate profit on these agreements as the difference between total estimated revenue and expected costs to complete the performance obligation within the terms of the agreement and recognize the respective profit as the goods are produced. The estimates to determine the profit earned on the performance obligation are based on anticipated selling prices and historical cost of goods sold and represent our best judgement at the time. Changes in judgements on these above estimates could impact the timing and amount of revenue recognized with a resulting impact on the timing and amount of associated profit.   On occasion our customers provide materials to be used in the manufacturing process and the fair value of the materials is included in revenue as noncash consideration at the point in time when the manufacturing process commences along with the same corresponding amount recorded as cost of goods sold. The inclusion of noncash consideration has no impact on overall profitability.   12     Contract Assets Contract assets, recorded as such in the Condensed Consolidated Balance Sheets, consist of unbilled amounts related to revenue recognized over time. Significant changes in the contract assets balance during the three months ended March 31, 2022 was as follows (in thousands):   Three Months Ended March 31, 2022         Outstanding at January 1, 2022   $ 8,698   Increase (decrease) attributed to:         Transferred to receivables from contract assets recognized     ( 7,773 ) Product transferred over time     7,189   Outstanding at March 31, 2022   $ 8,114     We expect substantially all the remaining performance obligations for the contract assets recorded as of March 31, 2022, to be transferred to receivables within 90 days, with any remaining amounts to be transferred within 180 days. We bill our customers upon shipment with payment terms of up to 120 days.   The following tables summarize our net sales by market for the three ended March 31, 2022 and 2021, respectively:       Three Months Ended March 31, 2022       Product/ Service Transferred Over Time     Product Transferred at Point in Time     Noncash Consideration     Total Net Sales by Market   Medical   $ 9,806     $ 4,915     $ 544     $ 15,265   Industrial     6,529       1,791       347       8,667   Aerospace and Defense     6,057       425       296       6,778   Total net sales   $ 22,392     $ 7,131     $ 1,187     $ 30,710         Three Months Ended March 31, 2021       Product/ Service Transferred Over Time     Product Transferred at Point in Time     Noncash Consideration     Total Net Sales by Market   Medical   $ 8,959     $ 2,893     $ 490     $ 12,342   Industrial     4,630       1,336       252       6,218   Aerospace and Defense     3,064       262       186       3,512   Total net sales   $ 16,653     $ 4,491     $ 928     $ 22,072     13       NOTE 4. FINANCING ARRANGEMENTS   We have a credit agreement with Bank of America which was entered into on June 15, 2017 and provides for a line of credit arrangement of $ 16,000 that expires on June 15, 2026.   Under the amended Bank of America credit agreement signed December 31, 2021, the line of credit is subject to variations in the Bloomberg Short-Term Bank Yield (BSBY) index rate. Our line of credit bears interest at a weighted-average interest rate of 3.6 % and 3.5 % as of March 31, 2022 and December 31, 2021, respectively. We had borrowings on our line of credit of $ 7,579 and $ 9,016 outstanding as of March 31, 2022 and December 31, 2021, respectively. There are no subjective acceleration clauses under the credit agreement that would accelerate the maturity of our outstanding borrowings. The line of credit is shown net of debt issuance costs of $ 53 and $ 58 on the consolidated balance sheet for the periods ended March 31, 2022 and December 31, 2021, respectively.   The line of credit and real estate term notes with Bank of America contain certain covenants which, among other things, require us to adhere to regular reporting requirements, abide by annual shareholder dividend limitations, maintain certain financial performance, and limit the amount of annual capital expenditures.   The Bank of America Credit Agreement provides for, among other things, a Fixed Charge Coverage Ratio of not less than 1.0 to 1.0, for the twelve months ending December 31, 2020 and each Fiscal Quarter end thereafter subject only during a trigger period commencing when our availability under our line is less than $2,000 until availability is above that amount for 30 days. The Company met the covenants for the period ended March 31, 2022.   At March 31, 2022, we had unused availability under our line of credit of $ 8,021 supported by our borrowing base. The line is secured by substantially all of our assets. In the first quarter of 2022, we amended our credit agreement to include the Employee Retention Credit Receivable as security in our line of credit which improved our unused availability.   14       NOTE 5. LEASES   We have operating leases for certain manufacturing sites, office space, and equipment. Most leases include the option to renew, with renewal terms that can extend the lease term from one to five years or more. Right-of-use lease assets and lease liabilities are recognized at the commencement date based on the present value of the remaining lease payments over the lease term which includes renewal periods we are reasonably certain to exercise. Our leases do not contain any material residual value guarantees or material restrictive covenants. At March 31, 2022, we do not have material lease commitments that have not commenced.   The components of lease expense were as follows:       March 31,     March 31,   Lease Cost   2022     2021   Operating lease cost   $ 581     $ 531   Finance lease interest cost     94       23   Finance lease amortization expense     182       163   Total lease cost   $ 857     $ 717     Supplemental balance sheet information related to leases was as follows:     Balance Sheet Location   March 31, 2022     December 31, 2021   Assets                   Operating lease assets Operating lease assets   $ 8,706     $ 8,983   Finance lease assets Property, Plant and Equipment     1,869       2,052                     Total leased assets   $ 10,575     $ 11,035     Supplemental cash flow information related to leases was as follows:     March 31,     March 31,       2022     2021   Operating leases                 Cash paid for amounts included in the measurement of lease liabilities   $ 434     $ 357   Right-of-use assets obtained in exchange for lease obligations   $ -     $ 858     15     Maturities of lease liabilities were as follows:       Operating Leases     Finance Leases     Total   Remaining 2022   $ 1,321     $ 460     $ 1,781   2023     1,810       409       2,219   2024     1,509       357       1,866   2025     1,255       103       1,358   2026     1,217       115       1,332   Thereafter     7,066       -       7,066   Total lease payments   $ 14,178     $ 1,444     $ 15,622   Less: Interest     ( 4,687 )     ( 112 )     ( 4,799 ) Present value of lease liabilities   $ 9,491     $ 1,332     $ 10,823     The lease term and discount rate at March 31, 2022 were as follows:   Weighted-average remaining lease term (years)         Operating leases     9.3   Finance leases     3.0   Weighted-average discount rate         Operating leases     7.7 % Finance leases     5.2 %     NOTE 6. INCOME TAXES   On a quarterly basis, we estimate what our effective tax rate will be for the full fiscal year and record a quarterly income tax provision based on the anticipated rate. As the year progresses, we refine our estimate based on the facts and circumstances, including discrete events, by each tax jurisdiction. Our effective tax rate for the three months ended March 31, 2022 and 2021 was ( 94 )% and 31 %, respectively. The primary drivers of the change in the effective tax rate is attributable to the US loss compared to book income on foreign entities and expected US book income for the year. There are also discrete items related to a release of valuation allowance from use of state attributes and non-qualified options exercised over book value.     NOTE 7. RESTRUCTURING CHARGES   During the first quarter of 2021, we recorded restructuring charges of $ 219  related to the consolidation of our production facilities and closure of our Merrifield, Minnesota facility. Loss on held for sale assets, relating to write downs to fair value, was $ 28 during the three months ended March 31, 2021. There were no restructuring charges or amounts accrued in the three months ended March 31, 2022.   16       NOTE 8. EMPLOYEE RETENTION CREDIT   On March 27, 2020, the Coronavirus Aid, Relief, and Economic Security Act (“CARES Act”) was signed into law providing numerous tax provisions and other stimulus measures, including an employee retention credit (“ERC”), which is a refundable tax credit against certain employment taxes. The Taxpayer Certainty and Disaster Tax Relief Act of 2020 and the American Rescue Plan Act of 2021 extended and expanded the availability of the ERC.   At March 31, 2022 and December 31, 2021, the Company has ERC benefits of $ 5,209 within Employee Retention Credits Receivable on the condensed consolidated balance sheet.     NOTE 9. RELATED PARTY TRANSACTIONS   David Kunin, our Chairman, is a minority owner of Abilitech Medical, Inc. Mr. Kunin also was a consultant to Abilitech, which relationship ended on March 1, 2021. In the three months ended March 31, 2022 and 2021, Abilitech paid the Company $ 54 and $ 268 , respectively, for delivery of medical products. The Company believes that transactions with Abilitech are on terms comparable to those that the Company could reasonably expect in an arm's length transaction with an unrelated third party.   David Kunin, our Chairman, is a minority owner (less than 10 %) of Marpe Technologies, LTD an early-stage medical device company dedicated to the early detection of skin cancer through full body scanners. Mr. Kunin is also a member of the Board of Directors of Marpe Technologies. The Company worked with Marpe Technologies to apply for a grant from the Israel-United States Binational Industrial Research and Development Foundation, a legal entity created by Agreement between the Government of the State of Israel and the Government of the United States of America (“BIRD Foundation”). The parties were successful in receiving approval for a $ 1,000 conditional grant. The Company and Marpe Technologies will each receive $500 from the BIRD Foundation and, among other obligations under the grant, each is required to contribute $500 to match grant funds from the BIRD Foundation. The Company will meet its obligation by providing certain services at cost or with respect to administrative services at no cost to Marpe Technologies. The total value of the contribution will not exceed $500. The Company will receive a 10 -year exclusive right to manufacture the products of Marpe Technologies. There can be no assurances that Marpe Technologies’ medical device will be commercially successful, that Marpe Technologies will be successful in raising additional funds to finance its operations or, if commercially successful, the Company will recoup the value of services provided to Marpe for which is not fully paid. The transactions between the Company and Marpe Technologies have been approved by the Audit Committee pursuant to the Company Related-Party Transactions Policy. During the three months ended March 31, 2022, we incurred expenses of $ 80 and recognized revenue of $ 89 . There were no expenses incurred or revenue recognized for the three months ended March 31, 2021. The Company believes that transactions with Marpe are on terms comparable to those that the Company could reasonably expect in an arm’s length transaction with an unrelated third party.   17       ITEM 2. MANAGEMENT ’ S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS   Overview   We are a Minnesota, United States based full-service global EMS contract manufacturer in the Medical, Aerospace & Defense and Industrial markets offering a full range of value-added engineering, technical and manufacturing services and support including project management, design, testing, prototyping, manufacturing, supply chain management and post-market services. Our products are complex electromedical and electromechanical products including medical devices, wire and cable assemblies, printed circuit board assemblies, higher-level assemblies, and other box builds for a wide range of industries. We serve three major markets within the EMS industry: Aerospace and Defense, Medical, and the Industrial market which includes industrial capital equipment, transportation, vision, agriculture, oil and gas. We maintain facilities in Bemidji, Blue Earth, Mankato, and Milaca, Minnesota; Monterrey, Mexico; and Suzhou, China. All of our facilities are certified to one or more of the ISO/AS standards, including 9001, AS9100 and 13485, with most having additional certifications based on the needs of the customers they serve.   Recent Developments   Global Pandemic The COVID-19 pandemic continued to impact our business in the first quarter of 2022 primarily driven by the emergence of the Omicron variant with a resulting increase in COVID cases in early 2022. During the first quarter of 2022, our performance was also adversely affected by continued supply chain disruptions and delays. The full extent to which COVID-19 will directly or indirectly impact our business, financial condition, and results of operations will depend on future developments that are highly uncertain and cannot be accurately predicted, including new information that may emerge concerning COVID-19, the actions taken to contain it or treat its impact and the economic impact on local, regional, national and international markets.   We will continue to assess the current and potential impacts of the COVID-19 pandemic on our business, financial condition, and results of operations. We actively manage our cash and working capital to preserve adequate liquidity and ensure that our business can continue to operate during these uncertain times.   18     Results of Operations   The following table presents statements of operations data as percentages of total net sales for the periods indicated:       Three Months Ended March 31,       2022     2021   Net Sales     100.0 %     100.0 % Cost of Goods Sold     86.8       92.9   Gross Profit     13.2       7.1                     Selling Expenses     2.7       3.3   General and Administrative Expenses     8.9       12.7   R&D Expenses     1.1       -   Restructuring Charges     -       1.0   Gain on Sale of Property and Equipment     (0.1 )     -   (Loss) Income from Operations     0.6       (9.9 )                   Interest Expense     (0.3 )     (0.3 ) (Loss) Income Before Income Taxes     0.3       (10.2 )                   Income Tax (Benefit) Expense     (0.2 )     (3.2 ) Net (Loss) Income     0.5 %     (7.0 )%   Net Sales   Net sales were $30.7 million in the first quarter of 2022, as compared to $22.1 million in the first quarter of the prior year, an increase of $8.6 million or 38.9% that was driven primarily due to higher production volume as well as price increases to counteract higher material and labor cost. We have also taken actions to scale the direct labor workforce and strengthen the supply chain for parts.   19     Net sales by our major industry markets for the three months ended March 31, 2022 and 2021 were as follows (in millions):       Three months Ended March 31,       2022     2021     % Change   Medical   $ 15.2     $ 12.3       23.6   Industrial     8.7       6.2       40.3   Aerospace and Defense     6.8       3.6       88.9   Total Net Sales   $ 30.7     $ 22.1       38.9     Net sales by timing of transfer of goods and services for the three ended March 31, 2022 is as follows (in millions):       Three Months Ended March 31, 2022       Product/ Service Transferred Over Time     Product Transferred at Point in Time     Noncash Consideration     Total Net Sales by Market   Medical   $ 9.8     $ 4.9     $ 0.5     $ 15.2   Industrial     6.5       1.8       0.4       8.7   Aerospace and Defense     6.1       0.4       0.3       6.8   Total net sales   $ 22.4     $ 7.1     $ 1.2     $ 30.7     Net sales by timing of transfer of goods and services for the three ended March 31, 2021 is as follows (in millions):       Three Months Ended March 31, 2021       Product/ Service Transferred Over Time     Product Transferred at Point in Time     Noncash Consideration     Total Net Sales by Market   Medical   $ 9.0     $ 2.9     $ 0.5     $ 12.4   Industrial     4.6       1.3       0.3       6.2   Aerospace and Defense     3.1       0.3       0.1       3.5   Total net sales   $ 16.7     $ 4.5     $ 0.9     $ 22.1     20     Backlog   Our 90-day shipment backlog as of March 31, 2022 was $35.4 million, a 4.1% decrease from the beginning of the quarter and a 13.8% increase from March 31, 2021. Backlog for our medical customers decreased 3.4% from the beginning of the quarter and increased 23.9% from the prior year. Our industrial customers’ backlog increased 9.0% from the beginning of the quarter and decreased 4.0% from the prior year. The aerospace and defense backlog decreased 21.1% from the beginning of the quarter and increased 17.6% from the prior year. Our backlog consists of firm purchase orders we expect to ship in the next 90 days, with any remaining amounts to be transferred within 180 days.   90-day shipment backlog by our major industry markets are as follows (in millions):       Shipment Backlog as of the Period Ended       March 31, 2022     December 31, 2021     March 31, 2021   Medical   $ 19.7     $ 20.4     $ 15.9   Industrial     9.7       8.9       10.1   Aerospace and Defense     6.0       7.6       5.1   Total 90-Day Backlog   $ 35.4     $ 36.9     $ 31.1     Our 90-day backlog varies due to order size, manufacturing delays, contract terms and conditions and timing from customer delivery schedules and releases. These variables cause inconsistencies in comparing the backlog from one period to the next. Our total shipment backlog was $97.6 million and $62.8 million as of March 31, 2022 and March 31, 2021, respectively. This backlog contains the contract assets which have been recognized as revenue.   Gross Profit   Gross profit as a percent of net sales 13.2% and 7.1% for the three months ended March 31, 2022 and 2021, respectively.  The gross profit improvement was primarily driven by higher production volume which increased plant utilization. Additionally, we did implement price increases in response to material and labor cost inflation.   Selling Expense   Selling expenses for the three months ended March 31, 2022 and 2021 was $0.8 million or 2.7% of sales and $0.7 million or 3.3% of sales, respectively.   General and Administrative Expense   General and administrative expenses for the three months ended March 31, 2022 and 2021 were held relatively flat, and are generally fixed in nature, at $2.7 million or 8.9% of sales and $2.8 million or 12.7% of sales, respectively.   21     Restructuring Charges   Restructuring charges for the three months ended March 31, 2021 was $0.2 million or 1.0% of sales. The restructuring charges are due to the closure of the Merrifield facility during 2021.   Research and Development Expense   Research and development expenses were $0.3 million or 1.1% of net sales for the three months ended March 31, 2022. There were no research and development expenses for the three months ended March 31, 2021.   Income (Loss) From Operations   First quarter 2022 income from operations was $169 thousand compared to a loss from operations of $2.3 million for the first quarter in 2021, driven by the increase in sales and gross margin as a percent of sales.   Interest Expense   Interest expense was $98 thousand and $86 thousand for the three months ended March 31, 2022 and 2021, respectively. The increase in interest expense relates to increased borrowings on the line of credit in the first quarter of 2022 compared to the first quarter of 2021.   Income Taxes   On a quarterly basis, we estimate what our effective tax rate will be for the full fiscal year and record a quarterly income tax provision based on the anticipated rate. As the year progresses, we refine our estimate based on the facts and circumstances, including discrete events, by each tax jurisdiction. Our effective tax rate for the three months ended March 31, 2022 and 2021 was (94)% and 31%, respectively. The primary drivers of the change in the effective tax rate is attributable to the US loss compared to book income on foreign entities and expected US book income for the year. There are also discrete items related to a release of valuation allowance from use of state attributes and NQO options exercised over book value.   Net Income (Loss)   Net income for the three months ended March 31, 2022 was $138 thousand or $0.05 per basic and diluted common share. Net loss for the three months ended March 31, 2021 of $1.6 million or $0.58 per basic and diluted common share.   Liquidity and Capital Resources   We believe that our existing financing arrangements, anticipated cash flows from operations, funds expected to be received for the ERC and cash on hand will be sufficient to satisfy our working capital needs for the next twelve months, capital expenditures and debt repayments.   22     Credit Facility   We have a credit agreement with Bank of America which was entered into on June 15, 2017 and provides for a line of credit arrangement of $16,000 that expires on June 15, 2026.   Under the amended Bank of America credit agreement signed December 31, 2021, the line of credit is subject to variations in the Bloomberg Short-Term Bank Yield (BSBY) index rate. Our line of credit bears interest at a weighted-average interest rate of 3.6% and 3.5% as of March 31, 2022 and December 31, 2021, respectively. We had borrowings on our line of credit of $7.6 million and $9.0 million outstanding as of March 31, 2022 and December 31, 2021, respectively. There are no subjective acceleration clauses under the credit agreement that would accelerate the maturity of our outstanding borrowings. The line of credit is shown net of debt issuance costs of $53 thousand and $57 thousand on the consolidated balance sheet for the periods ended March 31, 2022 and December 31, 2021, respectively.   The line of credit and real estate term notes with Bank of America contain certain covenants which, among other things, require us to adhere to regular reporting requirements, abide by annual shareholder dividend limitations, maintain certain financial performance, and limit the amount of annual capital expenditures.   The Bank of America Credit Agreement provides for, among other things, a Fixed Charge Coverage Ratio of not less than 1.0 to 1.0, for the twelve months ending December 31, 2020 and each Fiscal Quarter end thereafter subject only during a trigger period commencing when our availability under our line is less than $2.0 million until availability is above that amount for 30 days days. The Company met the covenants for the period ended March 31, 2022.   At March 31, 2022, we had unused availability under our line of credit of $8.0 million supported by our borrowing base. The line is secured by substantially all of our assets. In the first quarter of 2022, we amended our credit agreement to include the Employee Retention Credit Receivable as security in our line of credit which improved our unused availability.   Off-Balance Sheet Arrangements   We have not engaged in any off-balance sheet activities as defined in Item 303(a)(4) of Regulation S-K.   Critical Accounting Policies and Estimates   Our significant accounting policies and estimates are summarized in Management’s Discussion and Analysis of Financial Condition and Results of Operations in our Annual Report on Form 10-K for the year ended December 31, 2021. Some of our accounting policies require us to exercise significant judgment in selecting the appropriate assumptions for calculating financial estimates. Such judgments are subject to an inherent degree of uncertainty. These judgments are based on our historical experience, known trends in our industry, terms of existing contracts and other information from outside sources, as appropriate. Actual results could differ from these estimates.   23     Forward-Looking Statements   Those statements in the foregoing report that are not historical facts are forward-looking statements made pursuant to the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995.     ♦ Volatility in the marketplace which may affect market supply, demand of our products or currency exchange rates;   ♦ Supply chain disruption and unreliability;   ♦ Lack of supply of sufficient human resources to produce our products;   ♦ Increased competition from within the EMS industry or the decision of OEMs to cease or limit outsourcing;   ♦ Changes in the reliability and efficiency of our operating facilities or those of third parties;   ♦ Increases in certain raw material costs such as copper and oil;   ♦ Commodity and energy cost instability;   ♦ Risks related to FDA noncompliance;   ♦ The loss of a major customer;   ♦ General economic, financial and business conditions that could affect our financial condition and results of operations;   ♦ Increased or unanticipated costs related to compliance with securities and environmental regulation;   ♦ Disruption of global or local information management systems due to natural disaster or cyber-security incident;   ♦ Outbreaks of epidemic, pandemic, or contagious diseases, such as the recent novel coronavirus that affect our operations, our customers' operations or our suppliers' operations.   The factors identified above are believed to be important factors (but not necessarily all of the important factors) that could cause actual results to differ materially from those expressed in any forward-looking statement made by us. Discussion of these factors is also incorporated in Part I, Item 1A, “Risk Factors,” and should be considered an integral part of Part II, Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operations.” Unpredictable or unknown factors not discussed herein could also have material adverse effects on forward-looking statements. All forward-looking statements included in this Form 10-K are expressly qualified in their entirety by the forgoing cautionary statements. We undertake no obligations to update publicly any forward-looking statement (or its associated cautionary language) whether as a result of new information or future events.   Please refer to forward-looking statements and risks as previously disclosed in our Annual Report on Form 10-K for the fiscal year ended December 31, 2021.   24     ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK   Not applicable.   ITEM 4. CONTROLS AND PROCEDURES   Evaluation of Disclosure Controls and Procedures In accordance with Rule 13a-15(b) of the Securities Exchange Act of 1934 (the “Exchange Act”), as of the end of the period covered by this Quarterly Report on Form 10-Q, our management evaluated, with the participation of our Chief Executive Officer and Chief Financial Officer, the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rule 13a-15(e) and Rule 15d-15(e) under the Exchange Act). These controls and procedures are designed to ensure that information required to be disclosed in the Company’s Exchange Act reports is (1) recorded, processed, summarized and reported in a timely manner, and (2) accumulated and communicated to management, including the Company’s Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. Based upon their evaluation of these disclosure controls and procedures as of the date of the evaluation, the Chief Executive Officer and Chief Financial Officer concluded that the disclosure controls and procedures were effective.   Changes in Internal Control Over Financial Reporting   There was no change in our internal control over financial reporting during our most recently completed fiscal quarter that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.   25     PART II   ITEM 1. LEGAL PROCEEDINGS   We are subject to various legal proceedings and claims that arise in the ordinary course of business.   ITEM 1A. RISK FACTORS   We are affected by the risks specific to us as well as factors that affect all businesses operating in a global market. The significant factors known to us that could materially adversely affect our business, financial condition or operating results or could cause our actual results to differ materially from our expectations are described in our annual report on Form 10-K for the fiscal year ended under the heading “Part I – Item 1A.Risk Factors.” There have been no material changes in the risk factors from those disclosed in the Annual Report on Form 10-K for the year ended December 31, 2021.   ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS   As of March 31, 2022, our share repurchase program has expired, and no additional amounts are available for repurchase.   ITEM 3. DEFAULTS ON SENIOR SECURITIES   None.   ITEM 4. MINE SAFETY DISCLOSURES   Not applicable.   ITEM 5. OTHER INFORMATION   None.   26     ITEM 6. EXHIBITS   Exhibits     31.1* Certification of the Chief Executive Officer pursuant to Rule 13a-14(a) and Rule 15d-14(a), promulgated under the Securities Exchange Act of 1934, as amended.         31.2* Certification of the Chief Financial Officer pursuant to Rule 13a-14(a) and Rule 15d-14(a), promulgated under the Securities Exchange Act of 1934, as amended.         32* Certification of the Chief Executive Officer and Chief Financial Officer, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.         101* Financial statements from the quarterly report on Form 10-Q for the quarter ended March 31, 2022, formatted in Inline XBRL: (i) Condensed Consolidated Balance Sheets, (ii) Condensed Consolidated Statements of Operations and Comprehensive Loss, (iii) Condensed Consolidated Statements of Cash Flows, and (iv) the Condensed Notes to Condensed Consolidated Financial Statements.         104 Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).   *Filed herewith   27     Signatures ---------------   Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.     Nortech Systems Incorporated and Subsidiaries -------------------------------------------------------------     Date: May 10, 2022 by /s/ Jay D. Miller       Jay D. Miller   Chief Executive Officer and President   Nortech Systems Incorporated   Date: May 10, 2022 by /s/ Christopher D. Jones       Christopher D. Jones   Vice President and Chief Financial Officer   Nortech Systems Incorporated   28